API | vadadustat

vadadustat Report issue

Small molecule Experimental

AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW

Vadadustat, sold under the brand name Vafseo, is a medication used for the treatment of symptomatic anemia associated with chronic kidney disease. ^Wikipedia

Chemistry

SMILES: O=C(O)CNC(=O)c1ncc(-c2cccc(Cl)c2)cc1O
InChIKey: JGRXMPYUTJLTKT-UHFFFAOYSA-N
Mol. Mass: 306.71
ALogP: 1.92 Partition coefficient
ChEMBL Molecule:
vadadustat

More Chemistry

Pharmacology

Mechanisms of Action:
- Egl nine homolog 1 (Homo sapiens) ^UniProt
- Egl nine homolog 3 (Homo sapiens) ^UniProt
- Egl nine homolog 2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

akb-6548 | pg-1016548 | vadadustat

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (12)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (12)

Anemia (Phase 3)

Chronic Kidney Disease-Mineral and Bone Disorder (Phase 3)

Coronavirus Infections (Phase 2)

Drug Interactions (Phase 1)

Hamartoma (Phase 3)

Healthy Volunteers (Phase 3)

Kidney Diseases (Phase 2)

Kidney Failure, Chronic (Phase 2)

Liver Diseases (Phase 1)

Pharmacokinetics (Phase 1)

Renal Insufficiency, Chronic (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 37
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue